Health Catalyst (HCAT) Competitors

Health Catalyst (NASDAQ:HCAT) and Jamf (NASDAQ:JAMF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Which has stronger valuation & earnings, HCAT or JAMF?

Jamf has higher revenue and earnings than Health Catalyst. Jamf is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Catalyst	$302.06M	1.43	-$118.15M	-$1.35	-5.25
Jamf	$615.07M	3.05	-$110.09M	-$0.55	-26.73

Is HCAT or JAMF more profitable?

Jamf has a net margin of -11.29% compared to Health Catalyst's net margin of -26.20%. Jamf's return on equity of 0.00% beat Health Catalyst's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Catalyst	-26.20%	-7.51%	-3.72%
Jamf	-11.29%	N/A	N/A

Does the media prefer HCAT or JAMF?

In the previous week, Health Catalyst had 3 more articles in the media than Jamf. MarketBeat recorded 5 mentions for Health Catalyst and 2 mentions for Jamf. Health Catalyst's average media sentiment score of 0.87 beat Jamf's score of 0.70 indicating that Health Catalyst is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Health Catalyst	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jamf	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, HCAT or JAMF?

Health Catalyst has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Jamf has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500.

Does the MarketBeat Community favor HCAT or JAMF?

Health Catalyst received 105 more outperform votes than Jamf when rated by MarketBeat users. However, 70.67% of users gave Jamf an outperform vote while only 68.40% of users gave Health Catalyst an outperform vote.

Company	Underperform	Outperform
Health Catalyst	Outperform Votes 158 68.40%	Underperform Votes 73 31.60%
Jamf	Outperform Votes 53 70.67%	Underperform Votes 22 29.33%

Do analysts recommend HCAT or JAMF?

Health Catalyst currently has a consensus target price of $11.79, indicating a potential upside of 66.31%. Given Health Catalyst's stronger consensus rating and higher possible upside, equities analysts plainly believe Health Catalyst is more favorable than Jamf.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Catalyst	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Jamf	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Do insiders and institutionals hold more shares of HCAT or JAMF?

85.0% of Health Catalyst shares are held by institutional investors. Comparatively, 93.8% of Jamf shares are held by institutional investors. 2.5% of Health Catalyst shares are held by company insiders. Comparatively, 2.3% of Jamf shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Health Catalyst and Jamf tied by winning 9 of the 18 factors compared between the two stocks.